- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04654182
Evaluation of the Residual Antimicrobial Efficacy of One Test Material Based on a Modification of ASTM E1115-11 Test Method
February 24, 2021 updated by: Molnlycke Health Care AB
To evaluate the residual antimicrobial effectiveness of one test product when tested using a modification of the methodology of the standardized ASTM E115-11 (2017)
Study Overview
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Montana
-
Bozeman, Montana, United States, 59718
- Bioscience Laboratories, Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects may be of either sex, between the ages of 18 and 65 years, and of any race.
- Subjects must be able to read and understand English.
- Subjects must possess both hands and all ten digits.
- Subjects must have an average baseline population of at least 1.0 x 105 colony forming units (CFU) per hand.
- Subjects must have no active skin rashes, dermatoses, hangnails, or breaks in the skin of the hands or forearms. Subjects must also have no inflammatory skin conditions, such as dermatitis, eczema, or psoriasis, anywhere on the body.
- Subjects must be in good general health and have no medical diagnosis of a physical condition, such as a current or recent severe illness, a heart murmur, mitral valve prolapse with heart murmur, congenital heart disease, an organ transplant, medicated or uncontrolled diabetes, hepatitis B, hepatitis C, an immunocompromised condition such as AIDS (or HIV positive), lupus, fibromyalgia, ulcerative colitis, Crohn's disease, asthma, heart disease, hypertension, or medicated multiple sclerosis.
- Subjects must have read and signed the Informed Consent Form, List of Restricted Products, and Allowed and Restricted Products For Hand Cleaning During Coronavirus Disease 2019 (COVID-19) Pandemic prior to participating in the study, all located in the separate Informed Consent documents. Subjects must also have a current Authorization to Use and Disclose Protected Health Information Form on file at the testing facility.
Exclusion Criteria:
- Have participated in a clinical study in the past 7 days or be currently participating in another clinical study.
- Wash the hands or applying lotion within the 2-hour period prior to baseline sampling or testing.
- Be experiencing any signs/symptoms of respiratory illness, including cough, fever (body temperature of ≥ 100.0 °F) or chills, shortness of breath or difficulty breathing, persistent pain or pressure in the chest, confusion or inability to respond to external stimuli, bluish lips/face, loss of taste/smell, sore throat, headache, nasal discharge ("runny nose"), frequent sneezing, or general fatigue / body aches.
- Have a current diagnosis of active Coronavirus Disease 2019 (COVID-19) or have been in close contact within the last 2 weeks of anyone who has been diagnosed as having contracted COVID-19.
- Have been regularly smoking or vaping over the past 2 years.
- Have limited mobility or dexterity that would hamper their ability to perform the study as directed.
- Have known allergies or sensitivities to latex (rubber), alcohols, sunscreens, deodorants, laundry detergents, topically applied fragrances, cleansers, soaps, lotions, or to common antibacterial agents, particularly chlorohexidine gluconate.
- Have experienced hives (raised welts) as a reaction to anything that contacted the skin with the exception of plants known to cause reactions for most humans (e.g., poison oak or poison ivy).
- Have a history of anaphylactic shock, anaphylactoid reaction, or anaphylactoid shock.
- Have a known hypersensitivity to the test product or any of its components, especially in those with a history of possible chlorhexidine-related allergic reactions.
- Contact the brain, cerebral membrane, middle ear and eyes with the test product and such contact must be avoided.
- Be receiving any antibiotic medications during the 7-day pre-test period through completion of the study.
- Be receiving any steroids (including steroid medications used to treat asthma) other than for contraception, hormone therapy, or menopausal purposes during the 7-day pre-test period through completion of the study.
- Have any type of port (or portacath) or Peripherally Inserted Central Catheter (PICC).
- Be nursing a child.
- Be pregnant, plan to become pregnant or impregnate a sexual partner within the pre-test and test periods of the study.
- Have any medical condition or use any medications that, in the opinion of the Principal Investigator, or Consulting Physician(s) should preclude participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Log reduction in bacterial count
Following pre-test period qualifying participants will wash their hands with 4% CHG product 3 times a day over the 5 day study period.
Bacterial counts will be taken at 6 and 12 hours after the final wash on day 5 and reductions calculated from the starting count to final count.
|
Product used in accordance with manufacturers Hand Hygiene instructions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bacterial counts
Time Frame: at 6 hours
|
Average Log reduction in counts
|
at 6 hours
|
Bacterial Counts
Time Frame: at 12 hours
|
Average Log reduction in counts
|
at 12 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2020
Primary Completion (Actual)
December 24, 2020
Study Completion (Actual)
December 24, 2020
Study Registration Dates
First Submitted
November 27, 2020
First Submitted That Met QC Criteria
November 27, 2020
First Posted (Actual)
December 4, 2020
Study Record Updates
Last Update Posted (Actual)
February 25, 2021
Last Update Submitted That Met QC Criteria
February 24, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- #2007591-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hand Hygiene
-
Otto-Friedrich-University BambergUniversity of TurkuEnrolling by invitation
-
Swiss Tropical & Public Health InstituteUniversity of Applied Sciences and Arts Northwestern Switzerland; Terre des...RecruitingHand Hygiene Effectiveness | Hand Hygiene BehaviorBurkina Faso, Mali
-
The Hong Kong Polytechnic UniversityNot yet recruiting
-
Sundara ReddyMicrodermis CorporationCompleted
-
University Hospital, Basel, SwitzerlandCompleted
-
London School of Hygiene and Tropical MedicineAcademic Centre for Dentistry in Amsterdam; Deutsche Gesellshaft fur Internationale...CompletedHand HygienePhilippines
-
Medline IndustriesNorthShore University HealthSystemNot yet recruiting
-
Istanbul Sultanbeyli State HospitalCompleted
-
Glasgow Caledonian UniversityTan Tock Seng Hospital; University of East Anglia; University of Strathclyde; NHS...CompletedHand HygieneUnited Kingdom
-
University Hospital, Basel, SwitzerlandNot yet recruiting
Clinical Trials on Chlorhexidine Gluconate
-
University of MilanCompleted
-
Universidad de GuanajuatoUnknownVentilator Associated Pneumonia | ChlorhexidineMexico
-
University of Sao PauloCompletedSurgical Site InfectionBrazil
-
Al-Iraqia UniversityCompleted
-
Liaquat National Hospital & Medical CollegeLiaquat College of Medicine and DentostryCompleted
-
Angela BiancoStryker NordicTerminatedCesarean Section | Surgical Site Infection | Nosocomial InfectionUnited States
-
Vanderbilt UniversityCompletedSurgical Site InfectionUnited States
-
Medline IndustriesCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Johns Hopkins UniversitySage Products, Inc.CompletedNosocomial InfectionsUnited States